Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
| Autor: | Andrew Yee, E. Bridget Kim, Noopur Raje |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty Standard of care Review Disease lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine risk stratification models Intervention (counseling) medicine In patient smoldering multiple myeloma Intensive care medicine Multiple myeloma business.industry Intensive treatment prognostic features lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Natural history early intervention 030104 developmental biology Prime time Oncology 030220 oncology & carcinogenesis business |
| Zdroj: | Cancers Cancers, Vol 12, Iss 1223, p 1223 (2020) |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers12051223 |
| Popis: | The current standard of care for smoldering multiple myeloma (SMM) is observation until there is end-organ involvement. With newer and more effective treatments available, a question that is increasingly asked is whether early intervention in patients with SMM will alter the natural history of their disease. Herein, we review the evolving definition of SMM and risk stratification models. We discuss evidence supporting early intervention for SMM—both as a preventative strategy to delay progression and as an intensive treatment strategy with a goal of potential cure. We highlight ongoing trials and focus on better defining who may require early intervention. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |